Lisdexamfetamine dimesylate is used in the treatment of Attention-deficit/hyperactivity disorder (ADHD) and for moderate to severe binge eating disorder in adults. Lisdexamfetamine Dimesylate was developed by Takeda Pharmaceutical.
The API has now reached off-patent status, after being launched in 2007.

The information provided above is sourced from Chemrobotics PharmaVetPat https://chemroboticspharma.com/pharmVetPat
to find out more, including patent landscape and routes of synthesis, please contact our sales team.

For enquiries regarding more detailed trade data of Lisdexamfetamine Dimesylate and many others, contact info@pharmacheminvestor.com